The Arg633 his substitution responsible for the private platelet antigen Gro(a) unravelled by SSCP analysis and direct sequencing Simsek, S.; Folman, C.C.; van der Schoot, C.E.; von dem Borne, A.E.G.Kr.
Summary. We have previously described the private or family platelet antigen, Gro a , which was identified in a case of neonatal alloimmune thrombocytopenia. The Gro a antigen was found to be located on the GP IIIa (b 3 ) subunit of the GP IIb/IIIa complex, the most prominent fibrinogen receptor of platelets. Initial experiments to characterize the Gro a antigen at the molecular genetic level were unsuccessful. We therefore decided to use a different strategy to unravel the molecular basis of this antigen. Platelet GP IIIa mRNA of a Gro(a þ ) and a Gro(a ¹ ) donor was amplified with suitable primers in a reverse transcriptase-polymerase chain reaction (RT-PCR) and subjected to single-strand conformational polymorphism (SSCP) analysis. Three regions of the amplified GP IIIa cDNA derived from the Gro(a þ ) donor showed a different SSCP pattern when compared to that of the Gro(a ¹ ) donor. Direct nucleotide sequence analysis of these three segments revealed that two of them contained silent substitutions, A1163C, A1553G and G1565A. The first and the latter changes were described previously. In the third segment a G1996A mutation was found, predicting an arginine → histidine substitution at position 633 of the mature glycoprotein. PCR-ASRA (allele-specific restriction enzyme analysis) performed on cDNA as well as on genomic DNA with the restriction enzyme MaeIII showed that the His633 form of GPIIIa is restricted to the Gro(a þ ) phenotype. The observed mutation is three amino acids upstream of the mutation underlying the HPA-8/Sr system (Arg636Cys), suggesting this region of GP IIIa to be susceptible for mutations. Moreover, the presence of a silent mutation and two low-frequency forms of the silent polymorphisms strongly suggests that the G1996A mutation did not occur in a direct ancestral allele.
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Human platelet antigens (HPA) can be targets for alloantibodies in neonatal alloimmune thrombocytopenia (NAITP) and transfusion reactions. HPAs are antigenic determinants of platelet membrane glycoproteins (Simsek & von dem Bourne, 1994) . The GP IIIa (b 3 ) subunit of the glycoprotein (GP) IIb/IIIa complex (Ginsberg et al, 1988; Phillips et al, 1991) (also known as the integrin a IIb b 3 ) (Hynes, 1987) , which functions as a fibrinogen receptor on platelets, carries the majority of these alloantigen determinants, i.e. those belonging to the HPA-1, -4, -6W, -7W, -8W systems (van der Schoot et al, 1986; Rosa & McEver, 1989; McFarland et al, 1993; Kuijpers et al, 1993; Kroll et al, 1990) . The recently described private platelet antigen Gro a also resides on GP IIIa (Simsek et al, 1994b) .
The basis for all known HPA systems lies in single point mutations, leading to a single amino acid substitution (Kuijpers et al, 1992 (Kuijpers et al, , 1993 Newman et al, 1989; Lyman et al, 1990; Wang et al, 1991 Wang et al, , 1993 Simsek et al, 1994a; Santoso et al, 1994; Noris et al, 1995) .
In a previous study the entire coding sequence of GP IIIa cDNA derived from a Gro(a þ ) donor was amplified in six overlapping fragments. Subsequent nucleotide sequence analysis of at least 16 randomly chosen subclones after subcloning the PCR products in the plasmid vector pUC18 did not show a consistent mutation that could be held responsible for the Gro a antigen (Simsek et al, 1994b) , which suggested that the Gro a antigen was the result of a posttranslational modification of GP IIIa.
However, in the present study we found that, by using a combination of single-strand conformational polymorphism (SSCP) ( Jin et al, 1993; Orita et al, 1989) (Santoso et al, 1994) , was found to be associated with the Gro a antigen.
MATERIAL AND METHODS
Blood. Blood from the family members and from unrelated healthy donors was drawn by venepuncture. The Gro(a) phenotype of the platelets was determined by the platelet immunofluorescence test (von dem Borne et al, 1978) and monoclonal antibody-specific immobilization of platelet antigens (MAIPA)-assay (Kiefel et al, 1987) . In the MAIPA technique, a combination of a monoclonal antibody directed against the b 3 -chain of the GP IIb/IIIa (aIIbb3) and antiGro a antibodies was used. Molecular characterization of the Gro a polymorphism. Platelet RNA and genomic DNA was prepared from Gro(a þ ) and Gro(a ¹ ) donors, according to established techniques (Chomczynski & Sacchi, 1987; Ciulla et al, 1988) .
cDNA was synthesized with 200 U of MoMuLV reverse transcriptase (RT) (GIBCO BRL, Grand Island, N.Y., U.S.A.), in a volume of 25 ml containing 7 . 5 ml stretched RNA template, 30 OD pd(N) 6 (Pharmacia, Uppsala), 0 . 5 mM dNTP mix (dATP, dCTP, dGTP, dTTP), 10 mM DTT, 30 U RNAsin (Promega, Madison, Wis.) and the 5× reaction buffer at 42ЊC according to the manufacturer's instructions. 50 ml of water were added to the cDNA mixture. Suitable oligonucleotide primers were used in the PCR to amplify the entire coding region of GP IIIa (Rosa et al, 1988) . PCR was performed with cDNA or genomic DNA as a template, 20 pmol of each primer and 2 U of Taq DNA polymerase in a buffer recommended by the manufacturer, in a total volume of 50 ml. The first cycle of the PCR was performed at 95ЊC for 5 min, followed by 34 cycles of 1 min at 95ЊC, 1 . 5 min at 52ЊC, 2 . 5 min at 72ЊC, and finally one cycle of 1 min at 95ЊC, 1 . 5 min at 52ЊC and 9 min 72ЊC.
Single-strand conformational polymorphism (SSCP). 11 overlapping segments of the cDNA coding for GP IIIa derived from Gro(a þ ) and Gro(a ¹ ) individuals were amplified and subjected to SSCP analysis ( Jin et al, 1993 ). An aliquot of PCR product (2 ml) was mixed with an equal volume (2 ml) of a solution containing 95% formamide, 0 . 5% bromophenol blue and 0 . 5% xylene cyanol. After 3 min of denaturation at 100ЊC, the samples were placed immediately on ice for at least 2 min. The samples were loaded on a nondenaturing gel (7 . 5% homogenous PhastGel) and electrophoresed with a PhastSystem at 320 V for 15 min at 15ЊC (Peyruchaud et al, 1995) . The gels were silverstained according to the method described in the PhastSystem manual (silver staining method optimilized for native PAGE). The PCR product (size 266 bp) in which an abnormal pattern was observed was amplified with oligonucleotide primers 21: 5 0 -tagaattC AAGTGTGAATGTGGCAGC-3 0 (nucleotides 1835-1853, extended at its 5 0 end with an EcoRI site) and 21A: 5 0 -GACGACACAGTCATCCTCATT-3 0 (nucleotides 2093-2073). The nucleotide sequence of the PCR products displaying conformational polymorphisms were determined directly by the dideoxy-chain-termination method (Sanger et al, 1977) using the Sequenase PCR Product Sequencing Kit (United States Biochemicals, Cleveland, Ohio, U.S.A.).
DNA typing for Gro a by PCR-ASRA (allele-specific restriction enzyme analysis). Oligonucleotide primers corresponding to genomic DNA sequences that flank the Gro a polymorphism, were designed in order to amplify this region (primers exon XIa: 5 0 -TTGCCTTAATCACTGTGTCCT-3 0 and exon XIb: 5 0 -CC TGGGTGTGTGCAACTCTAA-3 0 ) (Zimrin et al, 1990) . MaeIII restriction digestions of PCR products derived from genomic DNA were carried out under conditions recommended by the manufacturers (New England Biolabs, Beverly, Mass.). Restriction digests were analysed on 10% polyacrylamide gels.
RESULTS

RT-PCR and SSCP analysis
Eleven overlapping segments of the cDNA coding for GP IIIa derived from Gro(a þ ) and Gro(a ¹ ) individuals were amplified and subjected to SSCP analysis. Three segments from Gro(a þ ) subjects showed a different SSCP pattern when compared to these segments from Gro(a ¹ ) subjects. Fig 1  shows the abnormally migrating fragment that was generated from cDNA with oligonucleotide primers 21 and 21A, unique to the Gro(a þ ) sample (lane 2), compared to the Gro(a ¹ ) sample (lane 1). The nucleotide sequences of the three segments were determined in Gro(a þ ) and Gro(a ¹ ) individuals. They were compared with the previously reported sequence of GP IIIa (Rosa et al, 1988) . A single base change G → A at position 1996 (Fig 2) of the GP IIIa cDNA was identified, predicting an arginine (CGT) Gro(a ¹ ) allotype and histidine (CAT) in the Gro(a þ ) allotype at amino acid 633. Moreover, the Gro(a þ ) individual was found to be heterozygous for the reported silent nucleotide polymorphisms A↔C at position 1163 (Val355) and G↔A at position 1565. In addition, another silent nucleotide mutation G1553A (Glu485) was encountered in the Gro(a þ ) cDNA. No other mutations were found. Single-strand conformational polymorphism (SSCP) analysis of amplified GP IIIa cDNA derived from a Gro(a ¹ ) and Gro(a þ ) donor. GP IIIa cDNA was PCR amplified from nucleotides 1835-2093 (primers 21 and 21A). After amplification, an aliquot of the PCR fragment was subjected to SSCP analysis using the PhastGel system (non-denaturing gel electrophoresis and silver staining method). The SSCP pattern of the Gro(a ¹ ) sample shows two bands (lane 1), whereas that of the Gro(a þ ) sample shows more than two bands (lane 2).
Detection of the G → A polymorphism by MaeIII ASRA
Studies on cDNA. The G → A substitution at nucleotide 1996 results in the loss of a target site for the restriction enzyme MaeIII in the PCR product amplified from Gro(a þ ) cDNA. The digestion of the PCR products from Gro(a þ ) and Gro(a ¹ ) (primers 21A and 21) yielded fragments of the expected size (data not shown).
Studies on genomic DNA. Oligonucleotide primers exon XIa and XIb were used to amplify the polymorphic region in the GP IIIa genomic DNA derived from Gro(a þ ) and Gro(a ¹ ) ) individual is identical to the previously published sequence (Rosa et al, 1988) , a G at position 1996. The sequence derived from the Gro(a þ ) individual has also the G at position 1996, but in addition an A at the same position can be seen. The G → A mutation results in an Arg (CGT) to a His (CAT) substitution at amino acid position 633 of GP IIIa. (Fig 3) . The PCR product of 170 bp was subjected to MaeIII digestion and subsequently electrophoresed on a 10% polyacrylamide gel and stained with ethidium bromide. Note the target site for MaeIII present in both alleles, which can be regarded as an 'internal control' for the efficiency of the enzyme. Thus, in the Gro(a ¹ ) allele, the DNA comprising 170 bp is digested into three fragments of 94 bp, 67 bp and 9 bp, whereas in the Gro(a þ ) allele the 170 bp fragment is cut into two fragments of 103 bp and 67 bp because of the G → A change.
DISCUSSION
The platelet membrane GP IIb/IIIa complex (also called a IIb b 3 ) can bind fibrinogen, fibronectin, von Willebrand factor and vitronectin when platelets are activated (Phillips et al, 1991) . In addition to its pivotal function in haemostasis, the complex carries the majority of the human platelet alloantigens (Newman, 1994; von dem Borne et al, 1995) .
In previous studies the target of the private platelet alloantibody anti-Gro a was found to reside on the platelet GP IIIa (Simsek et al, 1994b ), but we were not able to establish the molecular basis of the Gro a antigen, i.e. none of the 16 subclones selected differed in Gro(a þ ) and Gro(a ¹ ) subjects. In the present study we applied the SSCP technique, which is a PCR-based methodology for identifying single base changes in a fragment of DNA. Platelet GP IIIa mRNA was amplified by PCR. After amplification, the PCR fragments were subjected to SSCP analysis. The nucleotide sequences of the PCR fragments which displayed a different SSCP pattern compared to normal controls were determined. This revealed a heterozygosity for a G → A mutation at base pair 1996 of the coding region of the mature protein, predicting a substitution of arginine (AAG) by histidine (GAG) at amino acid position 633, in the Gro(a þ ) form of GP IIIa. In addition to the G → A substitution at base pair 1996, three silent changes in heterozygous form were identified: (1) A↔C polymorphism at position 1163 (silent at amino acid level: Val355Val); (2) G↔A mutation at position 1553 (Glu485Glu); (3) G↔A polymorphism at position 1565 (Arg489Arg). Of the four mutations detected in the cDNA of GP IIIa, G1996A was most likely to be responsible for the Gro a alloantigen, because it represented the only mutation predicting an amino acid substitution, Arg633His. In Fig 4 a model for the generation of the Gro(a) haplotypes is shown. It is noteworthy that the nucleotide mutation, predicting to lead to the Gro(a) antigen, is contained within a GP IIIa isoform in which three other changes have occurred. This strongly suggests that the G1996A did not occur in an ancestral allele. The G1996A base change abolishes the target site for the restriction enzyme MaeIII in the Gro(a þ ) form of the GP IIIa DNA. We demonstrated by allele-specific restriction enzyme analysis (ASRA) with MaeIII of amplified cDNA, as well as of genomic DNA, that the G1996A mutation is indeed associated with the Gro a antigen. PCR-ASRA typing on genomic DNA is a useful technique, because it eliminates the need for the isolation of platelet RNA. Interestingly, the Gro a polymorphic site is located near the Sr a polymorphic site (HPA-8wb). Moreover, the wild-type amino acid is arginine in both polymorphisms. These findings suggest that this region of the GP IIIa gene is susceptible to mutations. The amino acid substitution does not have an effect on the expression of the GP IIb/IIIa complex on the platelet membrane, as was demonstrated in previous immunochemical studies (Simsek et al, 1994b) . The Gro(a þ ) individuals thus far studied have been found to be heterozygous and do not suffer from haemorrhagic diathesis or thrombosis.
In conclusion, we report that a G↔A polymorphism at base 1996 in the DNA encoding glycoprotein IIIa (b 3 ) is associated with the Gro a alloantigen. This further illustrates the polymorphic nature of GP IIIa.
